Selinexor (Nexpovio, Menarini Stemline) is indicated 'in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti‑CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy'.
The dosage schedule is available in the summary of product characteristics for selinexor.
The list price for selinexor is £3,680 per 8‑tablet pack of 20 mg tablets (excluding VAT, company submission; other pack sizes are available). So, a week of treatment on the standard dosage (8x20 mg) costs £3,680.
The company has a commercial arrangement. This makes selinexor available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.